# AbCellera Biologics Inc. (ABCL): MoatMap facts

As of 13 Nov 2026. Research data, not investment advice.

As of 13 Nov 2026, the MoatMap Score for AbCellera Biologics Inc. (ABCL) is 30/100, ranked against 25,000+ stocks in 38 markets (Quality 31, Value 24, Momentum 63, each scored against its sector).

- MoatMap Score: 30/100, a percentile across 25,000+ stocks in 38 markets (100 is best).
- Quality 31, Value 24, Momentum 63: each a 0-100 percentile within Healthcare.
- Position: #18,735 overall, #1,635 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 11.62 USD on 12 Nov 2026.
- Insider filings, last 180 days: directors bought USD 1.5M.

Source: https://moatmap.ai/stock/ABCL
How the scores work: https://moatmap.ai/methodology
Does the score work? Each tenth of the ranking is tracked monthly: https://moatmap.ai/decile-tracker